CD4 and neoplasm: Depletion of CD3+, but not CD4+ subsets in HPD1NR subcutaneous tumor-bearing hamsters had a significant detrimental impact on treatment efficacy suggesting that Ad-TD-nsIL-12 acts via a CD3+ CD4− (CD8+) mechanism to eliminate tumors (Fig. 7a, b).